SkyQuest, a renowned market research firm, has recently released a detailed report on the cell cryopreservation market. The report offers valuable insights and analysis on the industry, such as growth projections, segment breakdowns, emerging trends, and lucrative business prospects. This report is a reliable source of information for companies and individuals looking to invest in the market. The analysis provides a comprehensive view of the industry’s current state, along with predictions for future growth and potential areas of opportunity.
Westford, USA, March 10, 2023 (GLOBE NEWSWIRE) — The cell cryopreservation market is witnessing significant growth in North America, primarily due to the increasing cases of infertility among the population. Besides, major key players in the market for stem cells are investing heavily in research and development activities, fueling the growth of this market. In addition, the government’s recent support for developing novel medical equipment also contributes to the market’s growth. Furthermore, the growing geriatric population worldwide, coupled with the rising awareness about the benefits of cryopreservation cell lines and the high focus on drug development, are further expected to drive the market’s growth.
SkyQuest’s global research has revealed that a staggering 45 million couples and 178 million individuals of reproductive age worldwide struggle with infertility. This startling figure indicates a significant need for advanced medical treatments and technologies, including the emerging field of cell cryopreservation. Given the growing demand for infertility treatments and the increasing success rates of cell cryopreservation techniques, the market is poised for significant growth in the coming years.
Browse in-depth TOC on the “Cell Cryopreservation Market”
Pages – 245
Tables – 62
Figures – 75
Get a sample copy of this report:
https://skyquestt.com/sample-request/cell-cryopreservation-market
Cryopreservation is a vital technique in the medical field that involves preserving biological materials at extremely low temperatures. This process is critical in maintaining the viability of cells, tissues, and other biological constructs over extended periods. Cryopreservation is commonly used to store sperm, eggs, embryos, and tissues for transplant purposes or research studies.
Prominent Players in Cell Cryopreservation Market
ThermoFisher Inc.
Cytiva
Lonza
Corning Inc.
PromoCEll GmbH
Sigma Aldrich
Himedia Laboratories
Creative Biolabs
Sartorius AG
Eppendorf Corporate
GE Healthcare
Miltenyi Biotec
Merck KGaA
Nippon Genetics
AMS Biotechnology Limited
Promocell GmbH
Mediatech Inc.
Biolife Solutions Inc.
Browse summary of the report and Complete Table of Contents (ToC):
https://skyquestt.com/report/cell-cryopreservation-market
Cryopreservation Media Segment to Witness Swift Growth due to Rising Use of Cell Cryopreservation in Research, Drug Development, and Cell-Based Therapies
According to recent market research, the cryopreservation media segment emerged as the leading contributor to the growth of the cell cryopreservation market in 2022. This trend is expected to continue from 2023 to 2030. One of the key factors driving this growth is the increasing use of cryopreservation media in preserving cells used in cell therapy development. According to SkyQuest, more than 48% of all deaths globally are attributable to chronic diseases, including cardiovascular disease, type 2 diabetes, cancer, and chronic respiratory disease. This alarming statistic indicates the urgent need for innovative solutions to prevent and treat these conditions. One promising solution is cell cryopreservation, which involves freezing living cells to preserve them for future use.
The North American cell cryopreservation market is expected to hold the largest market share by the end of 2030 compared to other regions. This is due to the region’s increasing healthcare expenditure on research and development activities by pharmaceutical and biotech companies, which is estimated to impact the market in the coming years significantly. In addition, the pharmaceutical and biotech companies in the region are investing heavily in R&D activities to develop new and innovative drugs and therapies for various diseases, driving the demand for cell cryopreservation.
Pharmaceutical and Biotechnology Segment to Drive High Growth as Cell Cryopreservation Widely Used to Store and Transport Living Cells and Tissues
The pharmaceutical and biotechnology sector was the frontrunner in the cell cryopreservation market in 2022, and it is expected to maintain its dominant position in the future. The increasing demand for cell-based therapies and regenerative medicines has been a major factor driving the growth of this segment. The pharmaceutical and biotechnology industry has been at the forefront of these applications, relying heavily on cell-based assays and models for drug development and testing.
The Asia Pacific region is poised to witness the highest growth rate in the cell cryopreservation market between 2023 and 2030. This growth is due to various factors, including improving healthcare infrastructure and increasing product management operations. The optimization of cryopreservation is a rapidly developing segment in this region, which is expected to boost the demand for cryopreservation cell lines in Asia Pacific countries. In addition, the acceleration of product management operations is anticipated to boost market growth further, enabling more efficient and effective distribution of cryopreservation cell lines.
To succeed in the highly competitive field of the cell cryopreservation market, companies must stay updated with the latest industry trends and capitalize on emerging opportunities. SkyQuest’s report offers valuable insights and recommendations to help businesses expand their operations and make informed decisions that can lead to success in this dynamic market. By constantly monitoring and analyzing the market, companies can differentiate themselves from their competitors.
Speak to Analyst for your custom requirements:
https://skyquestt.com/speak-with-analyst/cell-cryopreservation-market
Key Developments in Cell Cryopreservation Market
FUJIFILM Irvine Scientific, Inc. has recently made an exciting announcement regarding the use of its cryopreservation medium in a clinical trial conducted by Vitro Biopharma. The world-renowned company specializes in developing and manufacturing serum-free and chemically defined cell culture media, specifically for bioproduction and cell therapy manufacturing. The use of this medium in a clinical trial is expected to advance the field of regenerative medicine by providing a viable alternative to traditional cryopreservation methods that utilize DMSO, a toxic substance.
BioPharma Dynamics, a leading player in the cell and gene therapy market, has recently announced the expansion of its product portfolio. The company now offers chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. These products are suitable for cell therapy applications at any stage. In addition, these products are designed to provide researchers and clinicians with the necessary tools to improve the efficiency, consistency, and safety of their cell therapy protocols.
LifeCell and Cellutions BioStorage have allied to provide high-quality cryopreservation services. Cryopreservation is preserving biological materials at extremely low temperatures, typically below -150°C, to maintain their viability and functionality for future use. The alliance between LifeCell and Cellutions BioStorage will offer advanced cryopreservation services to various clients, including research institutions, biotech and pharmaceutical companies, and individuals.
Key Questions Answered in Cell Cryopreservation Market Report
How do external factors impact the growth of industries in the global market, and what are the economic, political, and social factors drive this growth?
Can you share case studies of companies that have implemented innovative strategies to succeed in the global market, and what are some common themes among these strategies?
Which regions are expected to experience the most significant sales and revenue growth in the global market, and what factors contribute to this growth?
What are the key challenges vendors face when operating in the global market, and what strategies can they adopt to improve their competitive position and market share?
Related Reports in SkyQuest’s Library:
Global Animal Diagnostics Market
Global Microbiome Market
Global Non-Invasive Prenatal Testing (NIPT) Market
Global NGS Library Preparation Market
US Secondary Hyperparathyroidism Treatment (SHPT) Market
About Us:
SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.
Address:
1 Apache Way, Westford, Massachusetts 01886
Phone:
USA (+1) 617-230-0741
Email: sales@skyquestt.com
LinkedIn Facebook Twitter
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.
SVB Financial faced a perfect storm, but there are plenty of other banks that would face big losses if they were forced to dump securities to raise cash.
Silicon Valley Bank wasn't well positioned for rising interest rates, leading to losses and a dilutive capital raise. Other banks show similar red flags.
Sentiment shifts periodically on Wall Street, and you could argue Cathie Wood might be the prime example of fortune reversal. Once an investor favorite and hailed as a pioneer with a portfolio jam-packed with the novel and cutting-edge, Wood’s reputation has been tarnished over the past year and a half as her growth-oriented investing style went out of fashion in the post-pandemic climate. Does that mean Wood is ready to desert her strategy of backing innovative yet risky and often unprofitable
Silvergate served the cryptocurrency industry, while SVB was the bank for Silicon Valley tech startups.
The halt of trading shares of Silicon Valley Bank is setting off a cascade of selling throughout the financial sector.
On Thursday, bank stocks got hammered, and so did shares of brokerage firm Charles Schwab, which dropped 13%. On Friday the pain continued, with Schwab suffering another 6% decline by midday. No doubt many investors are scratching their heads as to why Schwab would fall in line with bank stocks.
It may go down in the history books about Silicon Valley: the time that its most prominent bank, a bank founded nearly 40 years earlier, inflicted such grievous injury on itself that it had to be rescued by another bank or else risk going down in flames in a single day. If you’re just catching up, here’s what happened: Silicon Valley Bank lost $1.8 billion in the sale of U.S. treasuries and mortgage-backed securities that it had invested in, owing to rising interest rates. The plan was to sell $1.25 billion of its common stock to investors, $500 million in convertible preferred shares, and $500 million of its common stock in a separate transaction to the private equity firm General Atlantic.
The crisis at two California banks sparked a CNBC discussion on cryptocurrency and technology in banking trends.
(Reuters) -The Federal Aviation Administration (FAA) on Friday approved Boeing to resume deliveries of its widebody 787 Dreamliner next week after the planemaker addressed recent concerns raised by the agency. The agency halted 787 deliveries on Feb. 23 due to a data analysis error related to the jet’s forward pressure bulkhead, which Boeing Co found after reviewing certification records. The FAA said Boeing had addressed those concerns.
U.S. stocks got smoked on Friday after the crucial jobs report came in warmer than expected and jitters over the stunning failure of Silicon Valley Bank (SIVB) continued to weigh on markets.
SVB Financial Group plunged 60% during the trading day and is down big again Friday. SIVB is the parent of Silicon Valley Bank which is a key part of the venture capital and startup ecosystem in the San Francisco area. SVB also announced a huge, planned capital raise to bolster its liquidity.
President and CEO Greg Becker sold $3.6 million of shares through a trading plan in late February. The company didn't immediately respond to a request for comment.
The spike in interest rates has been devastating for the value of their securities portfolios, meaning many carry around billions in unrealized losses that could pose a problem if funding dries up.
Financial seminars can be a really great starting point to vet for yourself where you are in your journey to retirement, so kudos to you for attending multiple! Just like those financial seminars, I have limited information on your financial situation so I can’t say for sure whether or not you’re set for retirement in a couple of years. For example, in retirement, you’ll have your pension and Social Security, which is great — not a lot of Americans have a pension anymore — but will those be the heavy drivers of your retirement income?
The bank, whose shares have lost 34% of their value in the past week, sought to calm investors on Friday.
The disclosures come after banking regulators shut California-based SVB after a failed share sale that triggered worries of a liquidity crisis, hammered bank stocks and rippled through global markets. Western Alliance reported total deposits of $61.5 billion and warned of a moderate decline from these levels by the end of the quarter due to seasonal and monthly activity, but affirmed its full-year deposit growth forecast of 13% to 17%. Its investment portfolio is less than 15% of total bank assets and only less than 2% of total bank assets is categorized as available for sale.
Stratasys' (SSYS) high-growth product launches, strategic collaborations and highly attractive valuation are likely to have made it a lucrative takeover target for Nano Dimension.
Spring is coming up , and investors will need to break out the crystal ball when looking at the market conditions. There’s a growing consensus that even though inflation is down from last summer’s peak, it has plateaued at a high level. Watching the situation from banking giant JPMorgan, CEO Jamie Dimon takes the view that we won’t be getting back to the Fed target of 2% any time soon. Furthermore, while Dimon hails an economy that is “doing quite well” with plenty of jobs to go round, he also s
(Bloomberg) — Government-bond yields fell the most since since 2008 after a US bank failure spurred traders to reassess the outlook for additional Federal Reserve rate hikes.Most Read from BloombergOne Bank Folds, Another Wobbles and Wall Street Asks If It’s a CrisisWhy Is Everyone Talking About SVB? Here's Everything We Know About the Bank Right NowSilicon Valley Bank Collapses in Biggest Failure Since 2008SVB Races to Prevent Bank Run as Funds Advise Pulling CashPeter Thiel’s Founders Fund Ad